Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects
Zhoujiang Chen1, Ranjith Kumar Kankala2, Zhiyong Yang3
1School of Food and Bioengineering, Institute for advanced study, Chengdu University, Chengdu 610106, Sichuan, PR China.
Abstract:
In recent years, antibody-based cancer therapy has emerged as one of the efficient therapeutic strategies, such as immune checkpoint inhibitors (ICIs), angiogenesis inhibitors, antibody-drug conjugates (ADCs), multi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells, among others. To date, various drug delivery platforms have been developed to improve the bioavailability, delivery convenience, and reduced toxicity towards increased therapeutic efficacy of antibodies. Herein, we emphasize the clinical manifestations of various antibody-based tumor therapies, highlighting their mechanisms and applications for cancer therapy. Further, based on the problems to be solved in the current clinical application of antibodies, and combined with the advanced drug delivery technologies, we discuss the roles of antibody-based drug delivery systems (DDSs) in cancer therapy, such as enhanced patient compliance and regulating the tumor microenvironment for combined therapy. By expounding the importance of DDSs and discussing the challenges and prospects of their implementation, we suggest that pharmaceutical enterprises and scientists develop appropriate antibody-based delivery platforms.
Insights
Antibody-based cancer therapies, including immune checkpoint inhibitors and antibody-drug conjugates, are advancing. Novel drug delivery systems (DDSs) enhance antibody efficacy, reduce toxicity, and improve patient compliance in cancer treatment.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Antibody-based therapies are key cancer treatments, including immune checkpoint inhibitors (ICIs), angiogenesis inhibitors, antibody-drug conjugates (ADCs), multi-specific antibodies, and CAR-T cells.
- Drug delivery platforms are crucial for improving antibody bioavailability, convenience, and reducing toxicity.
Purpose of the Study:
- To review clinical manifestations, mechanisms, and applications of antibody-based tumor therapies.
- To discuss the role of antibody-based drug delivery systems (DDSs) in addressing current clinical challenges and enhancing cancer therapy.
- To explore how DDSs can improve patient compliance and modulate the tumor microenvironment for combined therapies.
Main Methods:
- Literature review of antibody-based cancer therapies and drug delivery systems.
- Analysis of clinical applications, mechanisms of action, and challenges.
- Discussion of advanced drug delivery technologies integrated with antibody therapeutics.
Main Results:
- Antibody-based therapies offer diverse mechanisms for cancer treatment.
- Drug delivery systems significantly enhance the therapeutic potential of antibodies.
- DDSs can improve patient compliance and enable combination therapies by regulating the tumor microenvironment.
Conclusions:
- Antibody-based drug delivery systems are vital for optimizing cancer therapy.
- Addressing challenges and fostering development of antibody-based DDSs is crucial for future clinical success.
- Collaboration between pharmaceutical enterprises and scientists is recommended for developing effective antibody delivery platforms.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...